Bettina J. Kraus - Publications

Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.

Journal: JACC. Heart failure

Published: August 31, 2025

How to make cardiology clinical trials more inclusive.

Journal: Nature medicine

Published: April 10, 2024

Differential Modulation of Markers of Oxidative Stress and DNA Damage in Arterial Hypertension.

Journal: Antioxidants (Basel, Switzerland)

Published: October 04, 2023

How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: August 23, 2023

Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease.

Journal: ESC heart failure

Published: March 23, 2023

Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.

Journal: European journal of heart failure

Published: March 20, 2023

Medical Costs of Chronic Kidney Disease and Type 2 Diabetes Among Newly Diagnosed Heart Failure Patients With Reduced, Mildly Reduced, and Preserved Ejection Fraction.

Journal: The American journal of cardiology

Published: January 16, 2023

Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial.

Journal: European journal of heart failure

Published: November 04, 2022

The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction.

Journal: International journal of cardiology. Heart & vasculature

Published: August 01, 2022

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.

Journal: European heart journal

Published: December 02, 2021

Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.

Journal: European journal of heart failure

Published: October 06, 2021

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.

Journal: EClinicalMedicine

Published: May 17, 2021